Appili Therapeutics: A Strategic Acquisition by Aditxt

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) recently announced the mailing of the Management Information Circular in connection with the Special Meeting of Shareholders. This meeting is scheduled for November 6, 2024, and shareholders are encouraged to vote their shares as soon as possible, with a deadline of November 4, 2024. The acquisition by Aditxt Inc. (through its wholly-owned subsidiary, Adivir, Inc.) is a significant event that brings strategic benefits to Appili's shareholders and programs.


The acquisition represents a significant premium to Appili's recent trading price, providing shareholders with immediate value. Under the terms of the Arrangement, for each Appili Share, shareholders will receive US$0.467 in cash and 0.0000686251 of a share of Aditxt common stock (the "Aditxt Shares"), representing a value of approximately US$0.00013 per Appili Share based on the closing price of the Aditxt Shares on October 3, 2024.


The acquisition premium of approximately 60% compared to Appili's recent trading price is a testament to the strategic value of the deal. This premium also compares favorably to industry benchmarks, indicating that the acquisition is well-positioned to generate value for shareholders.

The acquisition by Aditxt brings several strategic benefits to Appili's shareholders and programs. Aditxt's expertise in development operations and commercialization will significantly accelerate the advancement of Appili's programs, including facilitating access to new U.S. non-dilutive funding sources, preparing ATI-1701 IND submission, and supporting manufacturing activities for ATI-1801. Additionally, the combined enterprise should enhance access to capital and accelerate the development of Appili's programs, such as LIKMEZ™ (ATI-1501), a proprietary taste-masked liquid suspension formulation of metronidazole.


The acquisition aligns with Aditxt's broader strategy of accelerating health innovations and expanding its presence into new markets. With two subsidiaries in immune health and precision diagnostics already established, the proposed acquisitions of Evofem Biosciences, Inc., and Appili seek to further extend Aditxt's presence into women's health and public health, supporting its continued expansion.

In conclusion, the acquisition of Appili Therapeutics by Aditxt is a strategic move that brings significant value to Appili's shareholders and programs. The acquisition premium, strategic benefits, and alignment with Aditxt's broader strategy make this a compelling deal for both parties involved. Shareholders are encouraged to vote their shares in favor of the Arrangement as soon as possible.